As proliferation is essential for progression from normal cells to tumor, certain markers specific to proliferating cells may permit detection of premalignant lesions. Here, we aimed to evaluate the possible value of a proliferation marker, minichromosome maintenance 2 (MCM2), in the early diagnosis of colorectal cancer, by analyzing the difference in MCM2 expression among normal mucosa, adenoma, and adenocarcinoma, and investigating the relationship of MCM2 expression in adenomas with clinicopathologic variables. Using immunohistochemistry and real-time reverse transcription-PCR, we observed that the expression of MCM2 protein was present on basal third to half of colonic crypts in normal mucosa, whereas throughout the epithelium in adenomas and adenocarcinomas, the expression of MCM2 mRNA in adenocarcinomas was significantly higher than in adenomas (P = 0.001), whereas the difference between adenoma and normal mucosa was not significant (P = 0.184); we also found that the expression of MCM2 mRNA tended to be increased in the adenomas with highgrade dysplasia, or in older patients, respectively, compared with those with low-grade dysplasia, and younger patients. These results suggested the potential value of MCM2 in early diagnosis of colorectal cancer.
Introduction
MCM2 is one of six members of the minichromosome maintenance protein. It serves as a 'licensing factor', which is essential for the initiation of DNA replication and for limiting replication to one round per cell cycle (Todorov et al., 1998; Tan et al., 2001) . Some studies showed that MCM2 was a specific marker of the cell cycle state in tissues and its expression was observed during all phases of the cell cycle; however, MCM2 was lost after exiting from the cell cycle, with rapid loss after differentiation and slower loss in quiescent (G0) cells (Todorov et al., 1998; Davies et al., 2002; Gonzalez et al., 2003) . As a result of the sensitivity of the antibody to MCM2 as a marker of cell cycle state and because of the aberrant entry into the cell cycle in dysplasia and malignancy, MCM2 protein has been proposed as a candidate marker for cancer screening, surveillance, and as prognostic marker (Todorov et al., 1995; Williams et al., 1998; Freeman et al., 1999; Hunt et al., 2002; Rodins et al., 2002) . Sirieix et al. (2003) also demonstrated that MCM2 surface positivity correlated with the severity of cell dysplasia. These observations have led to the rationale for using surface sampling techniques in combination with MCM2 staining to detect dysplasia and malignancy (Freeman et al., 1999; Davies et al., 2002; Sirieix et al., 2003) . Furthermore, Tan et al. (2001) showed that in comparison with two proliferative markers, proliferating cell nuclear antigen and Ki-67, MCM2 was a more sensitive proliferative marker in the evaluation of premalignant lesions.
In 2002, Davies et al. revealed that MCM2 was confined to the proliferative compartment in the basal third to half of the crypts of normal large bowel mucosa. In contrast, MCM2 was expressed throughout the epithelium, including in surface mucosa when colorectal adenomas or adenocarcinoma are present. Through analyzing the MCM2 expression of the colonocytes retrieved from stool, they detected MCM2-positive cells in all patients with colorectal cancer, and no one case was expressed with MCM2 in all control individuals . As a result, in the 2003 colorectal surgical conference of England and Northern Ireland, they advocated early screening of colorectal cancer by the detection of MCM2 expression in stool. However, as MCM2 is expressed in all epithelia throughout the crypts of adenoma and adenocarcinoma, MCM2-positive cells can also be detected in patients with colorectal adenomas. Therefore, all those patients whose stool was detected with MCM2-positive cells cannot be directly diagnosed as colorectal adenocarcinoma because of the exception of colorectal adenoma. Then, how can we know that those patients with MCM2-positive cells in stool have adenoma or adenocarcinoma? To answer this question, we should first find out whether the expression of MCM2 between colorectal adenoma and adenocarcinoma has any quantitative difference. Consequently, the quantitative difference in MCM2 expression between colorectal adenoma and adenocarcinoma has become a considerable subject and this difference perhaps offers an experimental foundation to identify adenomas from MCM2-positive cells in stool and present a supplement to enhance the practicability of MCM2 as a marker of the early detection for colorectal cancer. A quantitative comparison of MCM2 expression between colorectal adenomas and adenocarcinoma has, however, not previously been reported.
Materials and methods

Study population
The study included 12 patients with colonic adenocarcinomas, 33 with colonic adenomas and 12 accompanying normal colonic mucosa for comparison (taken from uninvolved morphologically normal colonic tissue distant from colonic cancer above 10 cm). All specimens were taken from patients who underwent operation or colonoscopy excision at the West China Hospital of Sichuan University between June 2004 and December 2004. None of the patients had received preoperative chemotherapy and/or radiotherapy. The specimens were flash-frozen in liquid nitrogen and stored at -1501C. Each specimen was divided into two parts, one for immunohistochemistry and the other for real-time reverse transcription (RT)-PCR. Polyp size and morphological character, as reported by the endoscopist, was categorized as small (1-9 mm) or large ( Z 10 mm), and classified morphological character of adenomas without pedicel tissue as sessile adenoma or as petiolate adenoma with pedicel tissue. 'Advanced' adenomas were defined as the presence of adenomas with high-grade dysplasia, villous histology, sessile morphology, a polyp size of at least 1 cm, or older age of patients. All specimens, according to the histological diagnose criteria of the World Health Organization, were examined by the pathologist at the Department of Pathology in the West China Hospital of Sichuan University to confirm their histopathologic type.
Immunohistochemistry
For immunohistochemical staining, from each sample block, five serial 4-mm sections were cut and placed on glass slides. Sections 1-4 were used for immunostaining, and section 5 was stained with hematoxylin and eosin; this latter section was reviewed and compared with the original slide of the Department of Pathology used for diagnostic purposes.
Sections were stained with polyclonal goat antibody against MCM2 (SC-9839, Santa Cruz Biotechnology, Santa Cruz, California, USA). Briefly, sections were deparaffinized and those to be stained with MCM2 were subjected to microware antigen retrieval in citrate buffer for 15 min, twice. The sections were incubated with a monoclonal MCM2 antibody of goat at 1/400 dilution overnight at 41C. The avidin-biotin detection method was used on a DAKO autostainer universal system (DAKO, Ely, UK). A negative control was performed by omission of the primary antibody of goat.
RNA extraction and cDNA preparation
The specimens were taken from -1501C refrigerator and 100 mg of tissues were picked up to put into a 1-ml polypropylene tube. Total RNA was isolated using TriZol LS reagent (Jinmei Biotech Co., Ltd, Shenzhen, China) as described previously (Yang et al., 2006) . The quality of the RNA was determined by electrophoresis through agarose gels and staining with ethidium bromide and the 18 and 28 s RNA bands were visualized under UV light. To generate cDNA, 5 ml RNA was first denatured at 701C with 2.5 mmol/l random hexamers (TaKaRa Biotechnology Co. Ltd, Dalian, China) for 5 min before quenching on ice; then a 10 mmol/l final of each of the four deoxynucleotide triphosphates, 20 U ribonuclease inhibitor, 100 U M-MLV and 5 Â M-MLV buffer (TaKaRa Biotechnology Co. Ltd) were added together to make up a final volume of 20 ml reaction mix. The reaction mix was incubated for 10 min at 201C and 1 h at 421C. The reverse transcriptase was inactivated at 951C for 10 min and cooling at 51C for 5 min.
Real-time PCR
Real-time PCR on a theoretical basis was performed using relative quantification protocol on an iCycler iQ System (Bio-Rad, California, USA). Equation (1) (Michael, 2001) was applied to calculate the relative expression ratio of the target gene (MCM2) in a sample versus a control in comparison with a reference gene (glyceraldehydes-3 phosphate dehydrogenase): 
Primers and probes
Specific primers and probes for MCM2 and GAPDH were designed based on sequence data from the ensemble database (http://www.ensembl.org). They were purchased from TaKaRa Biotechnology Co. Ltd (Table 1) . 
Results
Immunohistochemistry
In normal mucosa, the MCM2 expression was confined to the basal third to half of crypts and there was no expression on surface mucosa (Fig. 1a ). MCM2, however, was expressed in all epithelia throughout the crypts of adenoma and adenocarcinoma ( Fig. 1b and c) . No difference on the location of MCM2 expression between adenoma and adenocarcinoma was found, but the intensity of staining for MCM2 in adenocarcinoma seemed greater than that in the adenomas.
Real-time reverse transcription-PCR Comparison of minichromosome maintenance 2 mRNA levels between adenocarcinoma and adenoma
To further compare the general expression level of MCM2 in adenocarcinoma relative to adenomas and test the group difference for significance, we put the C t values 
GAPDH, glyceraldehydes-3 phosphate dehydrogenase; MCM2, minichromosome maintenance 2. Fig. 1 (a) Normal colonic mucosa ( Â200 magnification). MCM2 expression in healthy colon is confined to basal third to half of colonic crypts with no expression in surface mucosa (brown staining). (b) Tubular adenomas ( Â 200 magnification). In colonic adenoma, MCM2 expression is seen throughout epithelium, including in surface mucosa. (c) Descending colon adenocarcinoma ( Â 200 magnification). In colonic adenocarcinoma, MCM2 expression is also seen throughout epithelium. Although, the intensity of cell staining for MCM2 in adenocarcinomas seemed greater than that in adenomas. MCM2, minichromosome maintenance 2.
for reference and target genes both in the sample group (adenocarcinomas) and the control group (adenomas) into the REST-XL software to run it, and chose 2000 as the randomization number. The C t values for reference and target gene were jointly reallocated to the control and sample groups ( = pair-wise fixed reallocation) and the expression ratios were calculated on the basis of the Eq.
(1). Then, the randomization test was performed to test the group difference for significance; the numeric results of the randomization test were given in the randomization data output box. The relative amounts of MCM2 mRNA to glyceraldehydes-3 phosphate dehydrogenase mRNA in the adenocarcinoma group were significantly higher than those in the adenoma group (P = 0.001), and MCM2 was upregulated in the adenocarcinoma group (in comparison with the adenoma group) by the factor 463.38 ( Table 2) .
Comparison of minichromosome maintenance 2mRNA levels between adenoma and normal mucosa
Briefly, to adopt the earlier method described in the test, we put the C t values of reference and target genes both in normal bowel mucosa (control group) and adenomas (sample group) into the REST-XL software, and also chose 2000 as the randomization number. To run the software, we found that the expression of MCM2 mRNA was upregulated in the sample group, in comparison with the control group, by the factor 5.73. The difference, however, did not reach statistical significance (P = 0.184, Table 3 ).
Minichromosome maintenance 2 mRNA expression in adenomas in relation to clinicopathological variables
We examined the relationship of MCM2 mRNA expression in adenomas with patients' age, tumor size, morphologic type, grade of dysplasia, and histopathological type. As shown in Table 4 , the expression of MCM2 mRNA was upregulated in the sample group (advanced adenomas, those adenomas with clinicopathological characteristics indicative of malignance) in comparison with the respective control group. All of the above differences were, however, not statistically significant (P > 0.05, Table 4 ), although the P values of the two variables, age and grade of dysplasia, are extremely close to 0.05 (P = 0.059 and 0.068, respectively).
Discussion
MCM2, as a specific marker for cell proliferation, has been extensively studied in some cancers, but little is known about the diversification of MCM2 expression during the colorectal adenoma-carcinoma sequence. In this study, we first analyzed the localization of MCM2 protein expression by using immunohistochemical assay and quantified MCM2 RNA expression by means of realtime RT-PCR in a series of 12 normal mucosa samples, 33 colonic adenomas, and 12 adenocarcinomas. We found that the MCM2 protein was confined to the proliferative compartment in the basal third to half of the crypts in normal mucosa; by contrast, the MCM2 protein was expressed throughout the epithelium in adenomas or adenocarcinoma. These results of expressional location of MCM2 protein are in accordance with the results from Freeman et al. (1999) , Kearsey et al. (1996) and Davies et al. (2002) . Interestingly, our data first showed that MCM2 mRNA was significantly upregulated in adenocarcinomas in comparison with adenomas. However, there was no significant difference in the expression level of MCM2 mRNA between adenoma and normal mucosa. Taken together, the findings suggest that colonic adenocarcinoma could surpass adenomas in the capability of cell The ratio of MCM2 mRNA expression, presented as the fold change in adenocarcinomas normalized to an endogenous reference gene(GAPDH) and relative to the group of adenoma. The ratio of MCM2 mRNA expression, presented as the fold change in adenomas normalized to an endogenous reference gene(GAPDH) and relative to the group of normal mucosa. proliferation or numbers of cell entry into the cell cycle, and possibly imply that, compared with the sequence of normal mucosa-adenoma, cell proliferation plays an important role in the phase of adenoma malignant to adenocarcinoma. Similar results are reported by Hiroshi et al. (2001 ) Rocha et al. (1996 and Sandler et al. (2000) , who showed that proliferative activity was significantly elevated during the adenoma-carcinoma sequence by analyzing the expression of Ki-67 with immunohistochemistry. Therefore, this finding could provide a possibility and an experimental foundation to identify colonic adenomas from those patients whose stool has MCM2-positive cells by quantitative detection in colonocytes retrieved from the stool, and this finding also enhances the practicability of MCM2 as a marker of early detection for colonic cancer.
Adenomas are the precursors of most sporadic colorectal cancers. The adenoma-to-carcinoma sequence is characterized by recognizable histological changes. Lesions, starting with dysplastic aberrant crypt foci and benign tubular adenomas, have the potential to progress to advanced adenomas, which have a significant potential to transform into invasive adenocarcinomas (Huang et al., 2007) . In this study, according to the differences in macroscopic size, histopathologic type, morphologic type, grade of dysplasia, and patients' age (Rocha et al., 1996; Sandler et al., 2000) , we divided all samples of adenomas into different groups, and further compared the difference of MCM2 mRNA expression in each group. Although statistically significant links were not observed between MCM2 mRNA expression and different clinicopathologic characters, we also observed that the expression level of MCM2 mRNA in 'advanced' adenomas with villous type, high-grade dysplasia, larger size, sessile morphology, and older age of patients was upregulated in comparison with their respective control group. One of the reasons why the difference had no statistical significance may be because of the small number of the samples. Rocha Ramirez et al. (1996) also showed that patient age, polyp size, and morphology were the more statistically significant risk factors for malignancy in their patient group by way of follow-up. Our finding also demonstrated that adenomas with risk factors for malignancy, whose expression of proliferation marker-MCM2 was upregulated, have potential for cell proliferation or more cell entry into the cell cycle, and might be more likely to progress down the malignant pathway than those adenomas whose expression level of MCM2 mRNA is low. Furthermore, Jonkers et al. (2006) reported that, in their study of endoscopic follow-up of 383 patients with colorectal adenomas, 14 were discharged from the followup program by their treating physician because of their age or severe comorbidity, and 10 had not been compliant. Considering some of the patients' age, comorbidity, and compliance, quantitative detection of proliferation markers may also provide an estimate of the frequency of potentially cancerous conditions in the patient with colonic adenoma, and this estimate may be helpful for determining whether to have frequent surveillance of those patients with dysplastic lesion after colonoscopy excision and initiate other more costly evaluations for colonic cancer detection, although the histopathological diagnosis will remain the gold standard for malignant tumor.
In our study, we used the real-time RT-PCR method for the quantification of MCM2 mRNA expression and compared MCM2 mRNA expression between colonic adenomas and adenocarcinomas. The method, based on real-time analysis of PCR amplification and Taq-Man methodology, does not require post-PCR sample handling, thereby avoiding problems related to carryover; it possesses a wide dynamic range and has a high sample throughput (Bieche et al., 1999; David, 2002) . Finally, and above all, real-time PCR makes RNA quantitation much more accurate, sensitive and reproducible, because it is based on C t values established in the early exponential phase of the PCR rather than endpoint measurement of the amount of accumulated PCR product. Real-time PCR has good intra-assay and interassay reproducibility and yields statistical confidence values (Gibson et al., 1996; Bièche et al., 1999) .
In this study, we also utilized a new software tool, named REST-XL, to test group difference for significance with a newly developed randomization test (Manly, 1997; Horgan and Rouault, 2000) . In our study, where the quantities of MCM2 mRNA are derived from ratios and variance can be high, normal distributions would not be expected, and it is unclear how a parametric test could best be constructed. A randomization test, which makes no assumptions about the distribution of observations in populations, is a useful alternative to more standard parametric tests for analyzing experimental data. It is more flexible than nonparametric tests based on ranks (Mann-Whitney, Kruskal-Wallis, etc.) and does not suffer a reduction in power relative to parametric tests (t-tests, analysis of variance, etc.) (Horgan and Rouault, 2000) . Therefore, according to the reason mentioned earlier, we think that randomization test with a pair-wise reallocation was the most appropriate approach for this application and choose it for statistical use in this paper.
In summary, even though MCM2 was expressed in all epithelia throughout the crypts of adenoma and adenocarcinoma, our data first demonstrated that the level of MCM2 expression in adenocarcinoma was significantly higher than in adenoma. This difference in expression was an important first step to provide a possibility and experimental foundation for screening colonic adenoma in those patients whose stool has MCM2-positive cells and estimating patients with adenoma at risk for subsequent development of adenocarcinoma, as well as presenting a supplement for enhancing the practicability of MCM2 as a marker of early detection for colorectal cancer. Further studies are needed to clarify the prognostic value of MCM2 in adenoma, to explore MCM2 expression in different histopathologic types of colonic adenomas in a larger number of samples, and to detect those patients with colonic adenoma at risk for subsequent development of adenocarcinoma.
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